LIF and hepatocellular carcinoma: Moreover, we demonstrated that CVB‐D had a therapeutic potential by targeting LIF‐modulated mitophagy in patient‐derived xenograft (PDX) models, which would elucidate LIF as a druggable target and regulatory mechanisms and exploit CVB‐D as the novel small‐molecule inhibitor of LIF for future HCC drug discovery.